Haematologica, Vol 92, Issue 1, e1-e2 doi:10.3324/haematol.10255
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferreri, A.J.
Right arrow Articles by Ponzoni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreri, A.J.
Right arrow Articles by Ponzoni, M.

Online Only Articles

Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma

A.J. Ferreri1,, G.P. Dognini1, C. Verona1, C. Patriarca2, C. Doglioni3, M. Ponzoni3

1 Medical Oncology; San Raffaele H Scientific Institute, Milan, Italy
3 Pathology Units; Dept. of Oncology; San Raffaele H Scientific Institute, Milan, Italy
2 Division of Pathology; Ospedale di Melegnano, Melegnano, Italy

Correspondence: Andrés J. M. Ferreri, MD, Medical Oncology Unit Dept. of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 - Milan, Italy, Tel: 0039-02-26437649 Fax: 0039-02-26437625, e-mail: andres.ferreri{at}hsr.it

We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure. The loss of CD20 expression in B-cell lymphomas relapsing after rituximab is a well-known phenomenon, but its actual impact in DLBCL is difficult to estimate. This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas. Accordingly, every relapse, whenever possible, should be histologically assessed with diagnostic and immunophenotyping purposes.




This article has been cited by other articles:


Home page
 BloodHome page
J. Hiraga, A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, and T. Naoe
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Blood, May 14, 2009; 113(20): 4885 - 4893.
[Abstract] [Full Text] [PDF]